Literature DB >> 10594321

Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.

I Méchaly1, F Laurent, K Portet, J Serrano, G Cros.   

Abstract

Although [Arg(8)]vasopressin is a potent vasoconstrictor, it possesses vasorelaxant properties manifested either after vasopressin V1 receptor blockade or directly in some vascular beds. The nature of the receptor involved in the vasorelaxant effect of [deamino-Cys(1) D-Arg(8)]vasopressin (desmopressin), a vasopressin V2 receptor agonist, was studied on rat precontracted aortic rings by the use of highly selective new non-peptide vasopressin receptor antagonists. The present study demonstrates for the first time that desmopressin relaxant effect is antagonized by the vasopressin V2 receptor antagonist SR121463A, but also by the vasopressin V1A receptor antagonist SR49059, suggesting that desmopressin-induced relaxation is mediated by a receptor subtype sharing both V1A and V2 pharmacological profiles.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594321     DOI: 10.1016/s0014-2999(99)00641-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Desmopressin: in adults with nocturia.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Chronic hypertension increases aortic endothelial hydraulic conductivity by upregulating endothelial aquaporin-1 expression.

Authors:  Jimmy Toussaint; Chirag Bharavi Raval; Tieuvi Nguyen; Hadi Fadaifard; Shripad Joshi; George Wolberg; Steven Quarfordt; Kung-Ming Jan; David S Rumschitzki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

3.  Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test.

Authors:  Stella Chaviaras; Plato Mak; David Ralph; Lalitha Krishnan; Jillian H Broadbear
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.